Relationship between the acid-suppression efficacy of proton pump inhibitors and CYP2C19 genetic polymorphism in patients with peptic ulcer

Academic Journal of Xi'an Jiaotong University

Volumn 20, Issue 3, 2008, Pages 213-215

  Niu, Chunyan ^a   Luo, Jinyan ^b   Mu, Nila ^c   Wang, Xueqin ^b  

^a XI'AN MEDICAL UNIVERSITY   (China)

^b XI'AN JIAOTONG UNIVERSITY   (China)

^c XINJIANG MEDICAL UNIVERSITY   (China)

Author keywords

Acid suppression efficacy; CYP2C19 genetic polymorphism; Esomeprazole; Omeprazole; Rabeprazole

Indexed keywords

CYTOCHROME P450 2C19; ESOMEPRAZOLE; OMEPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE;

ADULT; ARTICLE; CIRCADIAN RHYTHM; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; GASTRIC PH MONITORING; GENETIC POLYMORPHISM; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; OPEN STUDY; PEPTIC ULCER; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STOMACH ACID SECRETION; STOMACH PH;

EID: 51549094359     PISSN: 16718267     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. de Morais. New-generation proton pump inhibitors: overcoming the limitations of early-generation agents [J]. Eur J Gastroenterol Hepatol, 2001, 13 (suppl. 1):S43-S47.
2. Sakai T, Aoyama N, Kita T. CYP2C19 genotype and pharmocokinetics of three proton pump inhibitors in healthy subjects [J]. Pharmaceutical Res, 2001, 18:721-727.
3. Sagar M, Tybring G, Dahl ML, et al. Effects of omeprazole on intragastric pH and plasma gastrin are dependent on the CYP2C19 polymorphism [J]. Gastroenterology, 2000, 119 (3): 670-676.
4. Gong J, Zhu YL, Luo JY, et al. The acid-inhibiting effect of famotidine with a single dose by injection in musle[J]. Zhong Hua Yi Xue Za Zhi, 1998, 37(11):762-765.
5. Peghini PL, Katz PO, Bracy NA, et al. Nocturnal recovery of gastric acid secretion with twice-daily dosing of proton pump inhibitors[J]. Am J Gastroenterol, 1998, 93:763-767.
6. de Morais SMF, Wilkinson GR, Blaisdell J, et al. The major genetic defect responsible for the polymorphism of S- mephenytoin in humans [J]. J Biol Chem, 1994, 269:15419-15422.
7. de Morais SMF, Wilkinson GR, Blaisdell J, et al. Identification of a new genetic defect responsible for the polymorphism of (S)- mephenytoin metabolism in Japanese [J]. Mol Pharmacol, 1994, 46:594-598.
8. Takahiro K, Chiba K, Takashi I. Genotyping of S-mephenytoin 4′-hydroxylation in an extend Japanese population [J]. Clin Pharmacol Ther, 1996, 60:661-666.
9. Furuta T, Ohashi K, Kosuge K. CYP2C19 genotype status and effect of omeprazole on intragastric pH in humans [J]. Clin Pharmacol Ther, 1999, 65(2):552-561
10. Ariizumi K, Ohara S, Koike T, et al. Therapeutic effects of 10 mg/ day rabeprazole administration on reflux esophagitis was not influenced by the CYP2C19 polymorphism [J]. J Gastroenterol Hepatol, 2006, 21(9):1428-1434.
11. Shimatani T, Moriwaki M, Xu J, et al. Acid-suppressive effects of rabeprazole: comparing 10mg and 20mg twice daily in Japanese Helicobacter pylori-negative and -positive CYP2C19 extensive metabolisers [J]. Dig Liver Dis, 2006, 38 (11):802-808.
12. Rew JS. Clinical use of proton pump inhibitors in gastrointestinal diseases [J]. Korean J Gastroenterol, 2006, 47(3): 181-190.
13. Hoshino E, Ishiyama A, Tsuchida T. PPI: new strategies for GERD [J]. Nippon Rinsho, 2004, 62(8):1570-1576.
14. Chen ZY, Xie HY, Zheng QS, et al. Pharmacokinetic and pharmacodynamic population modeling of orally administered rabeprazole in healthy Chinese volunteers by the NONMEM method [J]. Eur J Drug Metab Pharmacokinet, 2006, 31(1): 27-33.
15. Furuta T, Shirai N, Sugimoto M, et al. Influence of CYP2C19 pharmacogenetic polymorphism on proton pump inhibitor-based therapies [J]. Drug Metab Pharmacokinet, 2005, 20 (3):153-167.
16. Luo JY, Niu CY, Wang XQ, et al. Effcet of a single dose of rabeprazole on nocturnal acid breakthrough and nocturnal alkaline amplitude [J]. World J Gastroentero, 2003, 9(11): 2583-2586.
17. Andersson T, Rohss K, Bredberg E, et al. Pharmacokinetics and pharmacodynamics of esomeprazole, the S-isomer of omeprazole [J]. Aliment Pharmacol Ther, 2001, 15(6): 1563-1569.
18. Hassan-Alin M, Andersen T, -Rohss K, et al. Pharmacokinetics of esomeprazole after oral and intravenous administration of single and repeated doses to healthy subjects [J]. Eur J Pharmacol, 2000, 56(3):665-670.
19. Blume H, Donath F, Warnke A, et al. Pharmacokinetic drug interaction profiles of proton pump inhibitors [J]. Drug Saf, 2006, 29(9):769-784.
20. Lindberg P, Keeling D, Fryklund J, et al. Review article: Esomeprazole-enhanced bio-availability, specificity for the proton pump and inhibition of acid secretion [J]. Aliment Pharmacol Ther, 2003, 17(4):481-488.
21. He LH, Yin Y, You YH, et al. In-vitro activity of rabeprazole, lansoprazole, and esomeprazole against Helicobacter pylori [J]. Zhonghua Liu Xing Bing Xue Za Zhi, 2003, 24 (6):447-448.
22. Dent J. Review article: esomeprazole-the first proton pump inhibitor to be developed as an isomer [J]. Aliment Pharmacol Ther, 2003, 17 (Suppl 1):1-4.
23. Klok RM, Postma MJ, van Hout BA, et al. Meta-analysis: comparing the efficacy of proton pump inhibitors in short-term use [J]. Aliment Pharmacol Ther, 2003, 17(10):1237-1245.
24. Horn J. Review article: relationship between the metabolism and efficacy of proton pump inhibitor - focus on rabeprazole [J]. Aliment Pharmacol Ther, 2004, 20 (Suppl 6):11-19.
25. Shimatani T, Inoue M, Kuroiwa T, et al. Acid-suppressive effects of rabeprazole, omeprazole, and lansoprazole at reduced and standard doses: a crossover comparative study in homozygous extensive metabolizers of cytochrome P450 2C19 [J]. Clin Pharmacol Ther, 2006, 79(1):144-152.